SHR-1701 + liposomal irinotecan

SHR-1701 + liposomal irinotecan is a combination therapy being investigated for the treatment of advanced solid tumors, specifically esophageal squamous cell carcinoma (ESCC). SHR-1701 is a first-in-class bifunctional fusion protein designed to simultaneously target programmed death-ligand 1 (PD-L1) and transforming growth factor-beta (TGF-β). It consists of a monoclonal antibody against PD-L1 fused to the extracellular domain of the TGF-β receptor II (TGF-βRII), acting as a 'trap' to neutralize TGF-β within the tumor microenvironment and overcome immune resistance. Liposomal irinotecan (often referred to as Irinotecan Liposome (II) in Chinese clinical contexts) is a nanoparticle-encapsulated formulation of the topoisomerase I inhibitor irinotecan. This formulation is designed to enhance the pharmacokinetic profile of irinotecan, providing prolonged drug exposure and higher intratumoral concentrations compared to standard irinotecan. The combination aims to leverage the synergistic potential of dual checkpoint/cytokine inhibition and cytotoxic chemotherapy to improve outcomes in patients who have progressed on prior immunotherapy.

Other names

SHR-1701 + Irinotecan Liposome (II)